4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
14.40
-0.74 (-4.89%)
At close: Jul 19, 2024, 4:00 PM
14.55
+0.15 (1.04%)
Pre-market: Jul 22, 2024, 7:29 AM EDT
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for FDMT stock have an average target of 48.25, with a low estimate of 31 and a high estimate of 81. The average target predicts an increase of 235.07% from the current stock price of 14.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FDMT stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +177.78% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +150.00% | Jun 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +150.00% | May 13, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +177.78% | Apr 15, 2024 |
| Barclays | Barclays | Buy Initiates $45 | Buy | Initiates | $45 | +212.50% | Apr 15, 2024 |
Financial Forecast
Revenue This Year
5.75M
from 20.72M
Decreased by -72.28%
Revenue Next Year
7.40M
from 5.75M
Increased by 28.86%
EPS This Year
-3.05
from -2.58
EPS Next Year
-3.42
from -3.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.1M | 17.7M | 2.1M | 225.8M | 871.5M |
| Avg | 5.7M | 7.4M | 1.7M | 74.4M | 294.1M |
| Low | 29,400 | n/a | 980,000 | 1.8M | 10.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.4% | 208.9% | -71.6% | 13,218.6% | 1,071.0% |
| Avg | -72.3% | 28.9% | -77.1% | 4,290.6% | 295.2% |
| Low | -99.9% | - | -86.8% | 9.0% | -85.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.76 | -1.00 | -3.45 | -1.12 | 3.28 |
| Avg | -3.05 | -3.42 | -3.96 | -3.38 | -2.47 |
| Low | -3.22 | -4.46 | -4.31 | -4.79 | -6.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.